微波消融联合化疗治疗肝癌的临床观察

摘要

Objective To study the clinical efficacy and complication of microwave ablation combined with chemotherapy in patients with liver cancer.Methods Longitudinal study of the design method, follow the hospital in January 2014 to December 2016 in our hospital treatment of liver cancer in 80 cases.Were randomly divided into test group (n=40) and control group (n=40) people, the control group of patients receiving chemotherapy only, while the experimental group was treated with microwave ablation combined with chemotherapy.The clinical data of the two groups were collected and included, including the time of treatment, the time of hospitalization and the recurrence rate, survival rate and the complication caused by treatment in the three years after treatment.Results The clinical effective rate was 30.0％in the experimental group and 22.5％in the control group.There was no significant difference between the two groups (χ2=1.335, P＜0.05).The 1-year survival rate of the experimental group was 72.5％after the end of treatment.In the control group, 57.5％, the difference between the groups was not significant (P＞0.05).The 2-and 3-year survival rates in the test group were 52.5％and 35.0％higher than the control group, 22.5％and10.0％, respectively.The difference was statistically significant (P＜0.05).The incidence of complications and adverse reactions after treatment in the trial group was lower than that in the control group, and the difference between the groups was statistically significant (P＜0.05).ConclusionMicrowave ablation combined with chemotherapy in patients with liver cancer treatment more quickly, reduce the pain of patients, the effective continuation of the patient's life, reduce the recurrence rate, safe and reliable, high feasibility, suitable for extensive promotion.%目的 探讨微波消融联合化疗治疗肝癌的临床疗效及并发症状.方法 采用纵向列研究设计方法, 将80例肝癌患者随机分为试验组 (40例) 和对照组 (40例), 对照组患者仅接受化疗, 而试验组则接受微波消融联合化疗.收集整理2组患者临床资料, 主要包括患者接受治疗的时间, 住院时间和治疗后的3年时间内的复发率、存活率以及治疗引起的并发症.结果 试验组近期临床有效率为30.0％, 对照组临床有效率为22.5％, 2组差异有统计学意义 (χ2=4.335, P＜0.05) .试验组在结束治疗后1年生存率 (72.5％) 高于对照组 (57.5％), 但组间差异不明显 (P＞0.05);2、3年生存率试验组 (52.5％、35.0％) 高于对照组 (22.5％、10.0％), 差异有统计学意义 (P＜0.05) .试验组治疗后并发症及不良反应发生率均低于对照组, 组间对比差异有统计学意义 (P＜0.05) .结论 微波消融联合化疗对肝癌患者的治疗更加快速, 可以减少患者的痛苦, 提高患者生存率, 安全可靠, 可行性高, 适合广泛推广.